

#54 – Kevin Sayer, CEO of Dexcom: Continuous glucose monitors – impact of food, sleep, and stress on glucose, the unmatched power of CGM to drive behavioral change, and the exciting future of CGM
28 snips May 20, 2019
Kevin Sayer, CEO of Dexcom, shares his journey in medical devices and insights into continuous glucose monitors (CGMs). He highlights the profound impact of sleep and stress on glucose levels and how CGMs empower users to drive behavioral change. Sayer discusses exciting advancements, including the G6 model and partnerships aimed at improving accessibility. The conversation also delves into the complexities of diabetes management and the potential for CGMs to benefit not only diabetics but anyone looking to optimize health.
AI Snips
Chapters
Transcript
Episode notes
Chance Encounter
- Peter Attia and Kevin Sayer met on a plane after Sayer noticed Attia browsing watches.
- They bonded over watches and then discussed Dexcom, surprisingly discovering a shared interest.
CGM Technology
- Dexcom CGM measures glucose via an enzymatic reaction on a subcutaneous wire.
- Other analytes could potentially be measured with similar technology, but Dexcom currently focuses on glucose.
G5 vs. G6 Size
- Peter Attia's children dislodged his G5 sensor on several occasions due to its larger size.
- The G6, with its smaller form factor, has proven more resistant to accidental removal.